Yahoo Web Search

Search results

1. • 

     Nail Psoriasis

     Health via Yahoo News· 4 days ago

     Biopsy: Your provider might collect a biopsy (small skin sample) from the nail bed and send it to a laboratory for evaluation. Nail Psoriasis Treatment...

2. • 

     State board targets six prescription drugs to review for affordability for Marylanders

     Maryland Matters via Yahoo News· 7 hours ago

     The board will seek public comments, additional information and data over the next 60 days to...

3. • Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. -...

     Benzinga· 7 hours ago

     ALVO, today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid ...

4. • 

     InnoCare Pharma concludes subject enrolment Phase II psoriasis trial

     Clinical Trials Arena via Yahoo Finance· 5 days ago

     InnoCare Pharma has announced the completion of subject enrolment in the Phase II clinical trial of...

5. • AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...

     The Parsons Sun· 4 days ago

     - AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)

6. • TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...

     FOX 23 News Albany· 19 hours ago

     WASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...

7. • 

     Critics Say FDA's Use of Surrogate Markers Falling Short

     Medscape· 4 days ago

     As the FDA's use of surrogate endpoints in the drug approval process is increasing, researchers are...

8. • 

     7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

     InvestorPlace· 14 hours ago

     Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying...

9. • Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides...

     WKRN Nashville· 5 days ago

     Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing ...

10. • 

      Earnings call: Arcutis Biotherapeutics reports strong Q1 2024 growth

      Investing.com· 6 days ago

      Arcutis expressed confidence in its growth trajectory, citing improvements in gross-to-net (GTN)...